Advances in Clinical and Experimental Medicine
2015, vol. 24, nr 1, January-February, p. 167–172
Publication type: review article
The Quality of Life and Psychological, Social and Cognitive Functioning of Patients with Acromegaly
1 Division of Consulting Psychiatry and Neurobiological Research, Department of Psychiatry, Wroclaw Medical University, Poland
2 Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, Poland
Acromegaly is a rare and chronic disease, most often caused by a pituitary adenoma. Excessive secretion of the growth hormone (GH) leads to hepatic secretion of insulin-like growth factor-1 (IGF-1), which in turn causes characteristic changes in the patient’s appearance, many skeletal deformities and metabolic disorders. In addition to somatic symptoms, acromegalic patients demonstrate psychosocial and personality deficits, as well as common co-occurrence of mental disorders. There are few studies investigating acromegaly in Poland. In recent years, the concept of quality of life has become fundamental to understanding health problems. Studies dealing with acromegaly likewise tend to include assessments of quality of life of patients suffering from this endocrinopathy.
acromegaly, GH, quality of life, mental disorder, cognitive disorder.
- Kałużny M, Bolanowski M: Akromegalia – od mitów do faktów. Endokrynol Pol 2008, 59, 242–244.
- Beuschlein F, Strasburger CJ, Siegerstetter V, Moradpour D, Lichter P, Bidlingmaier M, Blum HE, Reincke M: Acromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphoma. N Engl J Med 2000, 342, 1871–1876.
- Boix E, Pico A, Pinedo R, Aranda I, Kovacs K: Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf) 2002, 57, 131–134.
- Melmed S, Ezrin C, Kovacs K, Goodmann RS, Frohman LA: Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet – cell tumor. N Engl J Med 1985, 312, 9–17.
- Karges B, Pfaffle R, Boehm BO, Karges W: Acromegaly induced by growth hormone replacement therapy. Horm Res 2004, 61, 165–169.
- Macintyre JG: Growth hormone and athletes. Sport Med 1987, 4, 129–142.
- Ben-Shlomo A, Melmed S: Acromegaly. Endocrinol Metab Clin N Am 2008, 37, 101–122.
- Chanson P, Salenave S: Acromegaly. Orphanet Journal of Rare Diseases 2008, 3, 17.
- Zaleska-Kręcicka M, Zatoński T, Bolanowski M, Zatońska K: ENT disorders in acromegalic patients. Adv Clin Exp Med 2006, 15, 549–551.
- Furman K, Ezzat S: Psychological features of acromegaly. Psychoter Psychosom 1998, 67, 147–153.
- Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J: Acromegaly. Best Pract Res Clin Endocrinol Metab 2009, 23, 555–574.
- Holdaway IM, Rajasoorya RC, Gamble GD: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89, 667–674.
- Nabarro JD: Acromegaly. Clin Endocrinol (Oxf) 1987, 26, 481–512.
- Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG: Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994, 73, 233–240.
- Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F: Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 2001, 4, 259–262.
- Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998, 83, 2730–2734.
- Sievers C, Dimopoulou C, Pfister H, Lieb R, Steffin B, Roemmler J, Schopohl J, Mueller M, Schneider HJ, Ising M, Wittchen HU, Stalla GK: Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin Endocrinol 2009, 71, 691–701.
- Hach B: An unusual psychopathologic case history in a patient with acromegaly. Nervenarzt 1976, 47, 456–459.
- Le Feuvre CM, Isaacs AJ, Franks OS: Bromocriptine-induced psychosis in acromegaly. Br Med J (Clin Res Ed) 1982, 285, 1315.
- Mattoo SK, Bhansali AK, Gupta N, Grover S, Malhotra R: Psychosocial morbidity in acromegaly: a study from India. Endocr 2008, 34, 17–22.
- Ruchala M, Stangierska I, Gurgul E, Stangierski A, Fajfer J, Sowinski J: The effect of octreotide treatment on somatic and psychological symptoms of acromegaly. Neuro Endocrinol Lett 2010, 3, 265–269.
- Sievers C, Ising M, Pfister H, Dimopoulou C, Schneider HJ, Roemmler J, Schopohl J, Stalla GK: Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and ageand gender-matched controls. Eur J Endocrinol 2009, 160, 367–373.
- Tanriverdi F, Yapislar H, Karaca Z, Unluhizarci K, Suer C, Kelestimur F: Evaluation of cognitive performance by using P300 auditory event related potentials (ERPs) in patients with growth hormone (GH) deficiency and acromegaly. Growth Hormone & IGF Research 2009, 19, 24–30.
- Leon-Carrion J, Martin-Rodriguez JF, Madrazo-Atutxa A, Soto-Moreno A, Venegas-Mareno E, Torres-Vela E, Benito-Lopez P, Galvez MA, Tinahones FJ, Leal-Cerro A: Evidence of cognitive and neurophysiological impairment in patients with untreated naive acromegaly. J Clin Endocrinol Metab 2010, 95, 4367–4379.
- Sievers C, Sämann PG, Pfister H, Dimopoulou C, Czisch M, Roemmler J, Schopohl J, Stalla GK, Zihl J: Cognitive function in acromegaly: description and brain volumetric correlates. Pituitary 2012, 350–357.
- Webb SM, Badia X: Quality of life in growth hormone deficiency and acromegaly. Endocrinol Metab Clin N Am 2007, 36, 221–232.
- Webb SM: Quality of Life in Acromegaly. Neuroendocrinology 2006, 83, 224–229.
- Badia X, Webb SM, Prieto L, Lara N: Acromegaly quality of life questionnaire (AcroQoL). Health Qual Life Outcomes 2004, 2, 13.